Results 41 to 50 of about 72,887 (326)

Targeting DNA damage response deficiency in the treatment of breast cancer [PDF]

Zhongguo aizheng zazhi, 2022
DNA damage response (DDR) deficiency has been one of the emerging targets in treating breast cancer in recent years. The DDR pathway is essential for the identification, signal transduction and repair of DNA damage.
JIN Yizi, LIN Mingxi, ZHANG Jian
doaj   +1 more source

Niraparib in ovarian cancer. results to date and clinical potential [PDF]

, 2017
Ovarian cancer is the first cause of death from gynaecological malignancy. Germline mutation in BRCA1 and 2, two genes involved in the mechanisms of reparation of DNA damage, are showed to be related with the incidence of breast and ovarian cancer, both ...
Benedetti Panici, Pierluigi, Caruso, Davide, Papa, Anselmo, Tomao, Federica, Tomao, Silverio, Vici, Patrizia   +5 more
core   +1 more source

Poly(ADP-ribose) polymerase inhibitors as cancer therapy

Frontiers in Bioscience, 2013
Poly(ADP-ribose) polymerase (PARP) inhibitors are pharmacologic agents which primarily inhibit the PARP-1 and PARP-2 enzymes within the cell. Inhibition of PARP results in failure of base-excision repair (BER) to correct single-stranded breaks in DNA.
John F, Hilton, Matthew J, Hadfield, Minh-Thu, Tran, Geoffrey I, Shapiro   +3 more
openaire   +2 more sources

Background-Quenched Aggregation-Induced Emission through Electrostatic Interactions for the Detection of Poly(ADP-ribose) Polymerase-1 Activity

Molecules, 2023
Poly(ADP-ribose) polymerase-1 (PARP1) is a potential biomarker and therapeutic target for cancers that can catalyze the poly-ADP-ribosylation of nicotinamide adenine dinucleotide (NAD+) onto the acceptor proteins to form long poly(ADP-ribose) (PAR ...
Fengli Gao, Ruimin Zhao, Liping Huang, Xinyao Yi   +3 more
doaj   +1 more source

Evaluation of melanin-targeted radiotherapy in combination with radiosensitizing drugs for the treatment of melanoma [PDF]

, 2014
The incidence of malignant melanoma is rising faster than that of any other cancer in the United States. An [131I]-labeled benzamide - [131I]MIP-1145 - selectively targets melanin, reduces melanoma tumor burden and increases survival in preclinical ...
Babich, John, Boyd, Marie, Hutchison, Sharon, Mairs, Robert, Rae, Colin, Tesson, Mathias   +5 more
core   +1 more source

Phase I study of the PARP inhibitor talazoparib with radiation therapy for locally recurrent gynecologic cancers

Clinical and Translational Radiation Oncology, 2020
Summary: PARP inhibitors have been shown to radiosensitize tumor cells in both in vitro and in vivo studies. This is a phase I study that aims to determine the safety, tolerability, and maximally tolerated dose of talazoparib, a PARP inhibitor, when ...
David S. Lakomy, Diana L. Urbauer, Shannon N. Westin, Lilie L. Lin   +3 more
doaj   +1 more source

Crystal structure of the catalytic fragment of murine poly(ADP-ribose) polymerase-2. [PDF]

, 2004
Poly(ADP-ribose) polymerase-1 (PARP-1) has become an important pharmacological target in the treatment of cancer due to its cellular role as a 'DNA-strand break sensor', which leads in part to resistance to some existing chemo- and radiological ...
Amé, J C, de Murcia, G, Good, V, Oliver, A W, Pearl, L H, Roe, S M   +5 more
core   +3 more sources

Poly (ADP-Ribose) Polymerase Inhibitors: Talazoparib in Ovarian Cancer and Beyond

Drugs in R&D, 2020
Genetic complexity and DNA damage repair defects are common in different cancer types and can induce tumor-specific vulnerabilities. Poly(ADP-ribose) polymerase (PARP) inhibitors exploit defects in the DNA repair pathway through synthetic lethality and ...
Stergios Boussios, Charlotte Abson, Michele Moschetta, Elie Rassy, Afroditi Karathanasi, Tahir Bhat, Faisal Ghumman, Matin Sheriff, Nicholas Pavlidis   +8 more
doaj   +1 more source

PARP-1 regulates DNA repair factor availability. [PDF]

, 2018
PARP-1 holds major functions on chromatin, DNA damage repair and transcriptional regulation, both of which are relevant in the context of cancer. Here, unbiased transcriptional profiling revealed the downstream transcriptional profile of PARP-1 enzymatic
Birbe, Ruth, Brand, Lucas J, Cendon-Florez, Ylenia, Chand, Saswati N., de Leeuw, Renée, Dicker, Adam, MD, PhD, Dylgjeri, Emanuela, Evans, Joseph, Feng, Felix Y, Gallagher, Peter, Gaur, Sanchaika, Gomella, Leonard G, Gordon, Nicolas, Han, Sumin, Huang, Fangjin, Kelly, William Kevin, Knudsen, Beatrice, Knudsen, Karen E, Lallas, Costas D, Leiby, Benjamin E, Mandigo, Amy C., McCann, Jennifer J, McCue, Peter, McNair, Christopher, Parsons, Theodore, Poudel Neupane, Neermala, Raj, Ganesh V, Schiewer, M J, Shafi, Ayesha A, Trabulsi, Edouard J, Visakorpi, Tapio, Zhao, Shuang G   +31 more
core   +2 more sources

Poly (ADP-Ribose) Polymerase Inhibitors in Patients With Urothelial Cancer

Clinical Genitourinary Cancer, 2023
Poly ADP-ribose polymerase inhibitors (PARPis) have clinical activity in several cancers. The rationale of their therapeutic use in urothelial cancer (UC) resides in the high homologous-recombination repair (HRR) deficiency (HRD) prevalence and potential cross-sensitivity with platinum-based chemotherapy (PBCT).
Gamba, Teresa, Paparo, Jessica, Panepinto, Olimpia, Dionisio, Rossana, Di Maio, Massimo, Vignani, Francesca   +5 more
openaire   +2 more sources